{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:50:20Z","timestamp":1775170220640,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Increased endogenous hydrogen sulfide (H<jats:sub>2<\/jats:sub>S) level by cystathionine \u03b2-synthase (CBS) has been shown to closely relate tumorigenesis. H<jats:sub>2<\/jats:sub>S promotes angiogenesis, stimulates bioenergy metabolism and inhibits selective phosphatases. However, the role of CBS and H<jats:sub>2<\/jats:sub>S in chronic myeloid leukemia (CML) remains elusive. In this study, we found that CBS and H<jats:sub>2<\/jats:sub>S levels were increased in the bone marrow mononuclear cells of pediatric CML patients, as well as in the CML-derived K562 cells and CBS expression levels were correlated with different disease phases. Inhibition of CBS reduced the proliferation of the CML primary bone marrow mononuclear cells and induced growth inhibition, apoptosis, cell cycle arrest, and migration suppression in K562 cells and tumor xenografts. The knockdown of CBS expression by shRNA and inhibiting CBS activity by AOAA decreased the endogenous H<jats:sub>2<\/jats:sub>S levels, promoted mitochondrial-related apoptosis and inhibited the NF-\u03baB-mediated gene expression. Our study suggests that inhibition of CBS induces cell apoptosis, as well as limits cell proliferation and migration, a potential target for the treatment of chronic myeloid leukemia.<\/jats:p>","DOI":"10.1038\/s41392-020-00410-5","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T20:56:01Z","timestamp":1612817761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Inhibition of cystathionine \u03b2-synthase promotes apoptosis and reduces cell proliferation in chronic myeloid leukemia"],"prefix":"10.1038","volume":"6","author":[{"given":"Dan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9928-889X","authenticated-orcid":false,"given":"Weihong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"410_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243, 290\u2013293 (1973).","journal-title":"Nature"},{"key":"410_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A. M., Witte, O. N. & Baltimore, D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene. Science 233, 212\u2013214 (1986).","journal-title":"Science"},{"key":"410_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(73)90562-X","volume":"301","author":"D Borgaonkar","year":"1973","unstructured":"Borgaonkar, D. Philadelphia-chromosome translocation and chronic myeloid leukemia. Lancet 301, 1250\u20131250 (1973).","journal-title":"Lancet"},{"key":"410_CR4","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1200\/JCO.1988.6.10.1569","volume":"6","author":"M Shtalrid","year":"1988","unstructured":"Shtalrid, M. et al. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. J. Clin. Oncol. 6, 1569\u20131575 (1988).","journal-title":"J. Clin. Oncol."},{"key":"410_CR5","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","volume":"83","author":"A Bedi","year":"1994","unstructured":"Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J. & Jones, R. J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 2038\u20132044 (1994).","journal-title":"Blood"},{"key":"410_CR6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4065\/81.7.973","volume":"81","author":"A Quint\u00e1s-Cardama","year":"2006","unstructured":"Quint\u00e1s-Cardama, A. & Cortes, J. E. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin. Proc. 81, 973\u2013988 (2006).","journal-title":"Mayo Clin. Proc."},{"key":"410_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4984-3","volume":"18","author":"E Di Felice","year":"2018","unstructured":"Di Felice, E. et al. The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study. BMC Cancer 18, 1069 (2018).","journal-title":"BMC Cancer"},{"key":"410_CR8","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann, R. et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31, 2398\u2013246 (2017).","journal-title":"Leukemia"},{"key":"410_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880 (2001).","journal-title":"Science"},{"key":"410_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/imr.12234","volume":"263","author":"TL Holyoake","year":"2015","unstructured":"Holyoake, T. L. & Helgason, G. V. Do we need more drugs for chronic myeloid leukemia? Immunol. Rev. 263, 106\u2013123 (2015).","journal-title":"Immunol. Rev."},{"key":"410_CR11","doi-asserted-by":"publisher","first-page":"C537","DOI":"10.1152\/ajpcell.00329.2016","volume":"312","author":"NL Kanagy","year":"2017","unstructured":"Kanagy, N. L., Szabo, C. & Papapetropoulos, A. Vascular biology of hydrogen sulfide. Am. J. Physiol. Cell Physiol. 312, C537\u2013c549 (2017).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"410_CR12","doi-asserted-by":"publisher","first-page":"6904327","DOI":"10.1155\/2016\/6904327","volume":"2016","author":"BV Nagpure","year":"2016","unstructured":"Nagpure, B. V. & Bian, J. S. Interaction of hydrogen sulfide with nitric oxide in the cardiovascular system. Oxid. Med. Cell Longev. 2016, 6904327 (2016).","journal-title":"Oxid. Med. Cell Longev."},{"key":"410_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/1871530318666180426100532","volume":"18","author":"LL Qian","year":"2018","unstructured":"Qian, L. L., Liu, X. Y., Chai, Q. & Wang, R. X. Hydrogen sulfide in diabetic complications: focus on molecular mechanisms. Endocr. Metab. Immune Disord. Drug Targets 18, 470\u2013476 (2018).","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"410_CR14","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.18632\/aging.101026","volume":"8","author":"BW Perridon","year":"2016","unstructured":"Perridon, B. W., Leuvenink, H. G., Hillebrands, J. L., van Goor, H. & Bos, E. M. The role of hydrogen sulfide in aging and age-related pathologies. Aging 8, 2264\u20132289 (2016).","journal-title":"Aging"},{"key":"410_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-3-319-18144-8_12","volume":"230","author":"MR Hellmich","year":"2015","unstructured":"Hellmich, M. R. & Szabo, C. Hydrogen sulfide and cancer. Handb. Exp. Pharm. 230, 233\u2013241 (2015).","journal-title":"Handb. Exp. Pharm."},{"key":"410_CR16","first-page":"3205125","volume":"2018","author":"H Zhu","year":"2018","unstructured":"Zhu, H., Blake, S., Chan, K. T., Pearson, R. B. & Kang, J. Cystathionine beta-synthase in physiology and cancer. Biomed. Res. Int. 2018, 3205125 (2018).","journal-title":"Biomed. Res. Int."},{"key":"410_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1089\/ars.2014.5933","volume":"22","author":"MR Hellmich","year":"2015","unstructured":"Hellmich, M. R., Coletta, C., Chao, C. & Szabo, C. The therapeutic potential of cystathionine beta-synthetase\/hydrogen sulfide inhibition in cancer. Antioxid. Redox Signal. 22, 424\u2013448 (2015).","journal-title":"Antioxid. Redox Signal."},{"key":"410_CR18","doi-asserted-by":"publisher","first-page":"12474","DOI":"10.1073\/pnas.1306241110","volume":"110","author":"C Szabo","year":"2013","unstructured":"Szabo, C. et al. Tumor-derived hydrogen sulfide, produced by cystathionine-beta-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc. Natl Acad. Sci. USA 110, 12474\u201312479 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"410_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079167","volume":"8","author":"S Bhattacharyya","year":"2013","unstructured":"Bhattacharyya, S. et al. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS ONE 8, e79167 (2013).","journal-title":"PLoS ONE"},{"key":"410_CR20","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.3892\/or.2017.5513","volume":"37","author":"H Jia","year":"2017","unstructured":"Jia, H. et al. Role of the cystathionine beta-synthase\/H2S system in liver cancer cells and the inhibitory effect of quinolone-indolone conjugate QIC2 on the system. Oncol. Rep. 37, 3001\u20133009 (2017).","journal-title":"Oncol. Rep."},{"key":"410_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.freeradbiomed.2015.05.024","volume":"86","author":"S Sen","year":"2015","unstructured":"Sen, S. et al. Role of cystathionine beta-synthase in human breast Cancer. Free Radic. Biol. Med. 86, 228\u2013238 (2015).","journal-title":"Free Radic. Biol. Med."},{"key":"410_CR22","doi-asserted-by":"publisher","first-page":"483.e481","DOI":"10.1016\/j.urology.2011.10.013","volume":"79","author":"H Guo","year":"2012","unstructured":"Guo, H. et al. Characterization of hydrogen sulfide and its synthases, cystathionine \u03b2-synthase and cystathionine \u03b3-lyase, in human prostatic tissue and cells. Urology 79, 483.e481\u2013483.e485 (2012).","journal-title":"Urology"},{"key":"410_CR23","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.bbabio.2010.04.004","volume":"1797","author":"E Lagoutte","year":"2010","unstructured":"Lagoutte, E. et al. Oxidation of hydrogen sulfide remains a priority in mammalian cells and causes reverse electron transfer in colonocytes. Biochim. Biophys. Acta 1797, 1500\u20131511 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"410_CR24","doi-asserted-by":"publisher","first-page":"21972","DOI":"10.1073\/pnas.0908047106","volume":"106","author":"A Papapetropoulos","year":"2009","unstructured":"Papapetropoulos, A. et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc. Natl Acad. Sci. USA 106, 21972\u201321977 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"410_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1042\/CBI20090368","volume":"34","author":"WJ Cai","year":"2010","unstructured":"Cai, W. J., Wang, M. J., Ju, L. H., Wang, C. & Zhu, Y. C. Hydrogen sulfide induces human colon cancer cell proliferation: role of Akt, ERK and p21. Cell Biol. Int. 34, 565\u2013572 (2010).","journal-title":"Cell Biol. Int."},{"key":"410_CR26","doi-asserted-by":"publisher","first-page":"ra86","DOI":"10.1126\/scisignal.2002329","volume":"4","author":"N Krishnan","year":"2011","unstructured":"Krishnan, N., Fu, C., Pappin, D. J. & Tonks, N. K. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response. Sci. Signal. 4, ra86 (2011).","journal-title":"Sci. Signal."},{"key":"410_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/ars.2017.7058","volume":"31","author":"X Cao","year":"2019","unstructured":"Cao, X. et al. A review of hydrogen sulfide synthesis, metabolism, and measurement: is modulation of hydrogen sulfide a novel therapeutic for cancer? Antioxid. Redox Signal. 31, 1\u201338 (2019).","journal-title":"Antioxid. Redox Signal."},{"key":"410_CR28","doi-asserted-by":"crossref","unstructured":"Zuhra, K., Augsburger, F., Majtan, T. & Szabo, C. Cystathionine-beta-synthase: molecular regulation and pharmacological inhibition. Biomolecules 10, 697 (2020).","DOI":"10.3390\/biom10050697"},{"key":"410_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4508-1","volume":"18","author":"J Breza Jr.","year":"2018","unstructured":"Breza, J. Jr. et al. Endogenous H2S producing enzymes are involved in apoptosis induction in clear cell renal cell carcinoma. BMC Cancer 18, 591 (2018).","journal-title":"BMC Cancer"},{"key":"410_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.niox.2014.03.001","volume":"41","author":"K Modis","year":"2014","unstructured":"Modis, K. et al. Effect of S-adenosyl-L-methionine (SAM), an allosteric activator of cystathionine-beta-synthase (CBS) on colorectal cancer cell proliferation and bioenergetics in vitro. Nitric Oxide 41, 146\u2013156 (2014).","journal-title":"Nitric Oxide"},{"key":"410_CR31","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1039\/C2AN36113B","volume":"138","author":"B Chen","year":"2013","unstructured":"Chen, B. et al. Fluorescent probe for highly selective and sensitive detection of hydrogen sulfide in living cells and cardiac tissues. Analyst 138, 946\u2013951 (2013).","journal-title":"Analyst"},{"key":"410_CR32","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/bph.12171","volume":"169","author":"A Asimakopoulou","year":"2013","unstructured":"Asimakopoulou, A. et al. Selectivity of commonly used pharmacological inhibitors for cystathionine beta synthase (CBS) and cystathionine gamma lyase (CSE). Br. J. Pharm. 169, 922\u2013932 (2013).","journal-title":"Br. J. Pharm."},{"key":"410_CR33","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/bph.12369","volume":"171","author":"C Szabo","year":"2014","unstructured":"Szabo, C. et al. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br. J. Pharm. 171, 2099\u20132122 (2014).","journal-title":"Br. J. Pharm."},{"key":"410_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3324\/haematol.2015.139337","volume":"101","author":"TI Mughal","year":"2016","unstructured":"Mughal, T. I. et al. Chronic myeloid leukemia: reminiscences and dreams. Haematologica 101, 541\u2013558 (2016).","journal-title":"Haematologica"},{"key":"410_CR35","first-page":"49","volume":"25","author":"JE Sokal","year":"1988","unstructured":"Sokal, J. E., Baccarani, M., Russo, D. & Tura, S. Staging and prognosis in chronic myelogenous leukemia. Semin. Hematol. 25, 49 (1988).","journal-title":"Semin. Hematol."},{"key":"410_CR36","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1002\/jcp.27145","volume":"234","author":"YY Yi","year":"2019","unstructured":"Yi, Y. Y. et al. Circular RNA of vimentin expression as a valuable predictor for acute myeloid leukemia development and prognosis. J. Cell Physiol. 234, 3711\u20133719 (2019).","journal-title":"J. Cell Physiol."},{"key":"410_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molcel.2011.10.021","volume":"45","author":"N Sen","year":"2012","unstructured":"Sen, N. et al. Hydrogen sulfide-linked sulfhydration of NF-kappaB mediates its antiapoptotic actions. Mol. Cell 45, 13\u201324 (2012).","journal-title":"Mol. Cell"},{"key":"410_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","volume":"125","author":"R Scheicher","year":"2015","unstructured":"Scheicher, R. et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 125, 90\u2013101 (2015).","journal-title":"Blood"},{"key":"410_CR39","first-page":"970","volume":"7","author":"T Miyagi","year":"1993","unstructured":"Miyagi, T. et al. Expression of the candidate Wilm\u2019s tumor gene, WT1, in human leukemia cells. Leukemia 7, 970\u2013977 (1993).","journal-title":"Leukemia"},{"key":"410_CR40","doi-asserted-by":"publisher","first-page":"9564","DOI":"10.18632\/oncotarget.2465","volume":"5","author":"A Berger","year":"2014","unstructured":"Berger, A., Sexl, V., Valent, P. & Moriggl, R. Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia. Oncotarget 5, 9564\u20139576 (2014).","journal-title":"Oncotarget"},{"key":"410_CR41","first-page":"1060","volume":"9","author":"HD Menssen","year":"1995","unstructured":"Menssen, H. D. et al. Presence of Wilms\u2019 tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9, 1060\u20131067 (1995).","journal-title":"Leukemia"},{"key":"410_CR42","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M Hoglund","year":"2015","unstructured":"Hoglund, M., Sandin, F. & Simonsson, B. Epidemiology of chronic myeloid leukaemia: an update. Ann. Hematol. 94, S241\u2013S247 (2015).","journal-title":"Ann. Hematol."},{"key":"410_CR43","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872\u2013884 (2013).","journal-title":"Blood"},{"key":"410_CR44","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","volume":"117","author":"P Jir\u00ed","year":"2011","unstructured":"Jir\u00ed, P., Szydlo, R. M., Goldman, J. M. & Apperley, J. F. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 117, 755\u2013763 (2011).","journal-title":"Blood"},{"key":"410_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","volume":"22","author":"PA Pophali","year":"2016","unstructured":"Pophali, P. A. & Patnaik, M. M. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 22, 40\u201350 (2016).","journal-title":"Cancer J."},{"key":"410_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel, O. & Superti-Furga, G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 33\u201344 (2004).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"410_CR47","doi-asserted-by":"publisher","first-page":"24113","DOI":"10.1074\/jbc.272.39.24113","volume":"272","author":"TS Finco","year":"1997","unstructured":"Finco, T. S. et al. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272, 24113\u201324116 (1997).","journal-title":"J. Biol. Chem."},{"key":"410_CR48","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1158\/0008-5472.CAN-09-4290","volume":"70","author":"DS Basseres","year":"2010","unstructured":"Basseres, D. S., Ebbs, A., Levantini, E. & Baldwin, A. S. Requirement of the NF-kappaB subunit p65\/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 70, 3537\u20133546 (2010).","journal-title":"Cancer Res."},{"key":"410_CR49","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.4049\/jimmunol.164.3.1355","volume":"164","author":"SA Reddy","year":"2000","unstructured":"Reddy, S. A., Huang, J. H. & Liao, W. S. Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-kappa B activation. J. Immunol. 164, 1355\u20131363 (2000).","journal-title":"J. Immunol."},{"key":"410_CR50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/(SICI)1097-4644(19990501)73:2<237::AID-JCB10>3.0.CO;2-H","volume":"73","author":"KH Shain","year":"1999","unstructured":"Shain, K. H., Jove, R. & Olashaw, N. E. Constitutive RelB activation in v-Src-transformed fibroblasts: requirement for IkappaB degradation. J. Cell Biochem. 73, 237\u2013247 (1999).","journal-title":"J. Cell Biochem."},{"key":"410_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel, B. & Schmid, J. A. The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer 12, 86 (2013).","journal-title":"Mol. Cancer"},{"key":"410_CR52","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0301-472X(03)00069-9","volume":"31","author":"D Kirchner","year":"2003","unstructured":"Kirchner, D. et al. Mechanisms of Bcr-Abl-mediated NF-\u03baB\/Rel activation. Exp. Hematol. 31, 504\u2013511 (2003).","journal-title":"Exp. Hematol."},{"key":"410_CR53","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.humpath.2003.08.020","volume":"35","author":"CE Bueso-Ramos","year":"2004","unstructured":"Bueso-Ramos, C. E. et al. Expression of constitutively active Nuclear-\u03baB RelA transcription factor in blasts of acute myeloid leukemia. Hum. Pathol. 35, 246\u2013253 (2004).","journal-title":"Hum. Pathol."},{"key":"410_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.leu.2403998","volume":"20","author":"D Cilloni","year":"2006","unstructured":"Cilloni, D. et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 20, 61\u201367 (2006).","journal-title":"Leukemia"},{"key":"410_CR55","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/sj.onc.1201411","volume":"15","author":"M Hamdane","year":"1997","unstructured":"Hamdane, M., David-Cordonnier, M. H. & D\u2019Halluin, J. C. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene 15, 2267\u20132275 (1997).","journal-title":"Oncogene"},{"key":"410_CR56","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1101\/gad.12.7.968","volume":"12","author":"JY Reuther","year":"1998","unstructured":"Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M. & Baldwin, A. S. Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 12, 968\u2013981 (1998).","journal-title":"Genes Dev."},{"key":"410_CR57","first-page":"159","volume":"349","author":"MC Arkan","year":"2010","unstructured":"Arkan, M. C. & Greten, F. R. IKK- and NF-\u03baB-mediated functions in carcinogenesis. Curr. Top. Microbiol. Immunol. 349, 159\u2013169 (2010).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"410_CR58","doi-asserted-by":"publisher","first-page":"66287","DOI":"10.18632\/oncotarget.11507","volume":"7","author":"G Carr\u00e0","year":"2016","unstructured":"Carr\u00e0, G. et al. The BCR-ABL\/NF-\u03baB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias. Oncotarget 7, 66287\u201366298 (2016).","journal-title":"Oncotarget"},{"key":"410_CR59","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2014-01-547943","volume":"123","author":"MY Hsieh","year":"2014","unstructured":"Hsieh, M. Y. & Van Etten, R. A. IKK-dependent activation of NF-kappaB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood 123, 2401\u20132411 (2014).","journal-title":"Blood"},{"key":"410_CR60","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ijc.24294","volume":"125","author":"N Lounnas","year":"2009","unstructured":"Lounnas, N. et al. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int. J. Cancer 125, 308\u2013317 (2009).","journal-title":"Int. J. Cancer"},{"key":"410_CR61","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nrd2425","volume":"6","author":"C Szabo","year":"2007","unstructured":"Szabo, C. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 6, 917\u2013935 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"410_CR62","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1189\/jlb.1006599","volume":"81","author":"L Zhi","year":"2007","unstructured":"Zhi, L., Ang, A. D., Zhang, H., Moore, P. K. & Bhatia, M. Hydrogen sulfide induces the synthesis of proinflammatory cytokines in human monocyte cell line U937 via the ERK-NF-kappaB pathway. J. Leukoc. Biol. 81, 1322\u20131332 (2007).","journal-title":"J. Leukoc. Biol."},{"key":"410_CR63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0165-4608(87)90354-2","volume":"28","author":"CT Fong","year":"1987","unstructured":"Fong, C. T. & Brodeur, G. M. Down\u2019s syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet. Cytogenet. 28, 55\u201376 (1987).","journal-title":"Cancer Genet. Cytogenet."},{"key":"410_CR64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","volume":"355","author":"H Hasle","year":"2000","unstructured":"Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome. Lancet 355, 165\u2013169 (2000).","journal-title":"Lancet"},{"key":"410_CR65","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pcl.2014.09.009","volume":"62","author":"KW Maloney","year":"2015","unstructured":"Maloney, K. W., Taub, J. W., Ravindranath, Y., Roberts, I. & Vyas, P. Down syndrome preleukemia and leukemia. Pediatr. Clin. North Am. 62, 121\u2013137 (2015).","journal-title":"Pediatr. Clin. North Am."},{"key":"410_CR66","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/ijc.21518","volume":"118","author":"K Patja","year":"2006","unstructured":"Patja, K., Pukkala, E., Sund, R., Iivanainen, M. & Kaski, M. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int. J. Cancer 118, 1769\u20131772 (2006).","journal-title":"Int. J. Cancer"},{"key":"410_CR67","doi-asserted-by":"publisher","first-page":"18769","DOI":"10.1073\/pnas.1911895116","volume":"116","author":"T Panagaki","year":"2019","unstructured":"Panagaki, T., Randi, E. B., Augsburger, F. & Szabo, C. Overproduction of H2S, generated by CBS, inhibits mitochondrial Complex IV and suppresses oxidative phosphorylation in Down syndrome. Proc. Natl Acad. Sci. USA 116, 18769\u201318771 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"410_CR68","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/ped.12876","volume":"58","author":"A Tanizawa","year":"2016","unstructured":"Tanizawa, A. Optimal management for pediatric chronic myeloid leukemia. Pediatr. Int. 58, 171\u2013179 (2016).","journal-title":"Pediatr. Int."},{"key":"410_CR69","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2119\/molmed.2016.00102","volume":"22","author":"C Chao","year":"2016","unstructured":"Chao, C. et al. Cystathionine-beta-synthase inhibition for colon cancer: enhancement of the efficacy of aminooxyacetic acid via the prodrug approach. Mol. Med. 22, 361\u2013379 (2016).","journal-title":"Mol. Med."},{"key":"410_CR70","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.phymed.2011.08.066","volume":"19","author":"QM Xu","year":"2012","unstructured":"Xu, Q. M. et al. Antitumor activity of Pulsatilla chinensis (Bunge) Regel saponins in human liver tumor 7402 cells in vitro and in vivo. Phytomedicine 19, 293\u2013300 (2012).","journal-title":"Phytomedicine"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00410-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T14:28:41Z","timestamp":1669818521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00410-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1038\/s41392-020-00410-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}